Immunity in Dengue
Abstract
The prototype strain of dengue 4 (H-241) received as viremic human serum, passaged once in a susceptible monkey, three times in Aedes albopictus and then 30 serial passages in primary dog kidney (PDK) cells was selected for preparation of candidate dengue vaccines for use in humans. Preparatory to seed virus production, the virus was cloned by three sequential terminal dilution procedures. Two vaccine lines were developed: A Master Seed was prepared at PDK passage 36 and Production Seed at PDK passage 37. Another Master Seed was prepared in Fetal rhesus lung cells (FRhL) from PDK passage 35 virus. The preparation of Production Seed (PDK-TD3 FRhLp2) and Candidate vaccine (PDK-TD3 FRhL-p3) have been completed during the contract period. Safety testing on the Production Seed is completed and results are satisfactory. It is anticipated that safety testing on the Candidate vaccine will be completed within the contract period. Biological marker studies continue to show that dengue 4 PDK35- TD3 passaged in FRhL maintains small plaque morphology, temperature shut-off below that of wild strain and reduced virulence for susceptible rhesus monkeys. Keywords: virus; arbovirus; dengue; vaccine; attenuation; immunity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1981
- Accession Number
- ADB094564
Entities
People
- S. B. Halstead
Organizations
- University of Hawaiʻi System